The combination of an anti-PD-1 immunotherapy and Lumacaftor, an FDA-approved small molecule inhibitor of DUSP18, impaired CRC growth in mice and synergistically enhanced antitumor immunity, and better survival in mouse models. Here, DUSP18 is linked to colorectal carcinoma.